Serotype 1 高ウイルス量C型慢性肝炎に対するペグインターフェロンα-2b, リバビリン併用療法の有用性 : 東北地区における多施設共同研究成績  [in Japanese] Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load : Results of multicenter trial in Tohoku area of Japan  [in Japanese]

Access this Article

Author(s)

    • 宮坂 昭生 MIYASAKA Akio
    • 岩手医科大学消化器・肝臓内科 Division of Gastroenterology and Hepatology, Iwate Medical University School of Medicine
    • 坂本 十一 SAKAMOTO Juichi
    • 弘前大学医学部消化器・血液・膠原病内科 Department of Gastroenterology and Hematology, Hirosaki University School of Medicine
    • 後藤 隆 GOTO Takashi
    • 秋田大学医学部内科学講座消化器内科学分野 Department of Gastroenterology, Akita University School of Medicine
    • 大西 洋英 OHNISHI Hirohide
    • 秋田大学医学部内科学講座消化器内科学分野 Department of Gastroenterology, Akita University School of Medicine
    • 大平 弘正 OHIRA Hiromasa
    • 福島県立医科大学消化器・リウマチ膠原病内科学講座 Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine
    • 阿部 弘一 ABE Koich
    • 岩手医科大学消化器・肝臓内科 Division of Gastroenterology and Hepatology, Iwate Medical University School of Medicine
    • 鈴木 一幸 SUZUKI Kazuyuki
    • 岩手医科大学消化器・肝臓内科 Division of Gastroenterology and Hepatology, Iwate Medical University School of Medicine
    • 河田 純男 Kawata Sumio
    • 山形大学医学部消化器内科学(現:兵庫県立西宮病院) Department of Gastroenterology, Yamagata University School of Medicine (Hyogo Prefectural Nishinomiya Hospital)

Abstract

セロタイプ1型(Serotype1)高ウイルス量のC型慢性肝炎256例を対象に48週間のペグインターフェロンα-2b(PEG-IFNα-2b)・リバビリン(Ribavirn)併用療法の治療効果,忍容性,安全性について検討した.副作用による中止率は17.8%で,53例に軽度から中等度の副作用が認められた.全例でのsustained viological response(SVR)率44.5%であった.56歳以上と比べて56歳未満の例ではSVR率が著明に高く,PEG-IFNα-2bもしくはRibavirnの減量または両剤減量例は非減量例と比べSVR率は低い傾向にあった.多変量解析では治療前BMI≥23.5,治療前ALT値≥62 IU/L,12週までのPEG-IFNα-2bのアドヒアランス(Adherence)≥80%,12週までのRibavirnのAdherence≥80%がSVRに寄与する有意な因子であった.以上より,serotype1で高ウイルス量のC型慢性肝炎に対する48週間のPEG-IFNα-2b・Ribavirn併用療法は安全で忍容性のある治療であると考えられた.<br>

We estimated 256 chronic hepatitis C (C-CH) patients with serotype 1 high viral load who received pegylaed interferon alfa-2b and ribavirin for 48 weeks. All patients were assessed for efficacy, tolerance and safety. Discontinuation of therapy for adverse events was 17.8% (45/256) for 48 weeks and 53 patients showed mild or moderate adverse events. The sustained virological response (SVR) rate was 44.5% (114/256). The SVR rate was significantly higher in patients less than 56 years old than more than 56 years old and was tend to be lower in the patients who reduced peylated interferon alfa-2b, ribavirin or both dosage than patients who received full dose. In logistic regression analysis, four independent factors were significantly associated with SVR; body mass index (= or >23.5), platelet counts (=or >16.4μ/<i>l</i>), adherence to pegylaed interferon alfa-2b (=or >80%) until 12 weeks and adherence to ribavirin (=or >80%) until 12 weeks. In conclusion, these results suggest that the combination therapy with pegylaed interferon alfa-2b and ribavirin may be safety and tolerance for C-CH patients with serogroup1 high viral load.<br>

Journal

  • Kanzo

    Kanzo 52(10), 652-661, 2011-10-25

    The Japan Society of Hepatology

References:  25

Codes

  • NII Article ID (NAID)
    10029822412
  • NII NACSIS-CAT ID (NCID)
    AN00047770
  • Text Lang
    JPN
  • Article Type
    ART
  • ISSN
    04514203
  • NDL Article ID
    11288580
  • NDL Source Classification
    ZS21(科学技術--医学--内科学)
  • NDL Call No.
    Z19-130
  • Data Source
    CJP  NDL  J-STAGE 
Page Top